New insulin candidate GZR33 enters human testing for type 1 diabetes
Disease control
Recruiting now
This early-stage trial is testing a new long-acting insulin called GZR33 in 12 adults with type 1 diabetes. The goal is to see how well it controls blood sugar compared to an existing insulin (degludec) and to check its safety. Participants will receive both insulins at different…
Phase: PHASE1 • Sponsor: Gan and Lee Pharmaceuticals, USA • Aim: Disease control
Last updated May 17, 2026 02:55 UTC